No further biomarker analyses have yet been published from CDK 4/6 inhibitor trials; for example, the Natalee trial (NCT03701334) examining ribociclib for adjuvant breast cancer patients will assess CCND1 as one of the biomarkers. Here, CCND1 is linked to breast carcinoma.